KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Gains from Investment Securities (2016 - 2025)

CRISPR Therapeutics AG's Gains from Investment Securities history spans 11 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 84.07% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, down 94.93%, while the annual FY2025 figure was $1.4 million, 80.91% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was $1.4 million at CRISPR Therapeutics AG, down from $7.4 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $53.1 million in Q4 2022 and bottomed at -$4.7 million in Q4 2021.
  • The 5-year median for Gains from Investment Securities is $1.2 million (2023), against an average of $5.2 million.
  • The largest annual shift saw Gains from Investment Securities plummeted 1050.73% in 2021 before it skyrocketed 1231.39% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at -$4.7 million in 2021, then surged by 1231.39% to $53.1 million in 2022, then tumbled by 96.0% to $2.1 million in 2023, then surged by 311.93% to $8.7 million in 2024, then plummeted by 84.07% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Gains from Investment Securities are $1.4 million (Q4 2025), $7.4 million (Q2 2025), and $257062.0 (Q1 2025).